Literature DB >> 14741722

Identification of a novel splice variant of the human anti-apoptopsis gene survivin.

Adel Badran1, Akira Yoshida, Keiko Ishikawa, Takanori Goi, Akio Yamaguchi, Takanori Ueda, Manabu Inuzuka.   

Abstract

Survivin, a new member of the inhibitor of apoptosis protein (IAP) family, has been reported to be expressed in many cancers but not in differentiated normal tissues. In the present study, we describe the identification of a novel alternatively spliced survivin transcript, designated as survivin-3B. It comprises 5 exons including novel exon 3B derived from a 165-bp long portion of intron 3. Acquisition of a new in-frame TGA stop codon within the novel exon 3B results in an open reading frame (ORF) of 363 nucleotides, predicting a truncated 120 amino acid protein. Expression of survivin-3B was detected in human colon and gastric adenocarcinoma cell lines as well as mononuclear cells prepared from patients with myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Survivin-3B contains a single baculovirus IAP repeat (BIR), which is critical for apoptosis inhibition. However, it lacks a carboxyl-terminal coiled-coil domain, suggesting that survivin-3B may not be associated with G2/M phase. These data indicate that the function of survivin-3B may be different from that of regular survivin.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14741722     DOI: 10.1016/j.bbrc.2003.12.178

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  45 in total

1.  Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer.

Authors:  Pablo E Vivas-Mejia; Cristian Rodriguez-Aguayo; Hee-Dong Han; Mian M K Shahzad; Fatma Valiyeva; Mineko Shibayama; Arturo Chavez-Reyes; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Clin Cancer Res       Date:  2011-04-21       Impact factor: 12.531

Review 2.  Nuclear or cytoplasmic expression of survivin: what is the significance?

Authors:  Fengzhi Li; Jie Yang; Nithya Ramnath; Milind M Javle; Dongfeng Tan
Journal:  Int J Cancer       Date:  2005-04-20       Impact factor: 7.396

3.  Dissecting the role of endothelial SURVIVIN DeltaEx3 in angiogenesis.

Authors:  Hugo Caldas; Jason R Fangusaro; Daniel R Boué; Michael P Holloway; Rachel A Altura
Journal:  Blood       Date:  2006-10-12       Impact factor: 22.113

4.  Isoform-specific silencing of the Livin gene by RNA interference defines Livin beta as key mediator of apoptosis inhibition in HeLa cells.

Authors:  Irena Crnković-Mertens; Julia Semzow; Felix Hoppe-Seyler; Karin Butz
Journal:  J Mol Med (Berl)       Date:  2005-12-31       Impact factor: 4.599

Review 5.  Survivin study: an update of "what is the next wave"?

Authors:  Fengzhi Li; Xiang Ling
Journal:  J Cell Physiol       Date:  2006-09       Impact factor: 6.384

6.  Survivin promoter -31G/C polymorphism in oral cancer cell lines.

Authors:  Salvatore de Maria; Lorenzo Lo Muzio; Alessandra Braca; Paolo Rega; Amalia Cassano; Angela Vinella; Ruggiero Fumarulo; Rosario Serpico; Ernesto Farina; Vittoria Metafora; Giuseppe Pannone; Gian Pietro Ravagnan; Salvatore Metafora; Corrado Rubini; Maria Carteni; Maria Addolorata Mariggiò
Journal:  Oncol Lett       Date:  2011-07-05       Impact factor: 2.967

Review 7.  Research progress on Livin protein: an inhibitor of apoptosis.

Authors:  Biao Yan
Journal:  Mol Cell Biochem       Date:  2011-05-27       Impact factor: 3.396

8.  Expression of survivin and its four splice variants in colorectal cancer and its clinical significances.

Authors:  Quan-Xing Ge; Yu-Yuan Li; Yu-Qiang Nie; Wen-Ge Zuo; Yan-Lei Du
Journal:  Med Oncol       Date:  2013-03-15       Impact factor: 3.064

9.  Expression of survivin and its splice variants in gastric cancer.

Authors:  Zhengjiang Cheng; Lihua Hu; Wenrong Fu; Qin Zhang; Xiaofeng Liao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-08

10.  Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs.

Authors:  T Iwasa; I Okamoto; K Takezawa; K Yamanaka; T Nakahara; A Kita; H Koutoku; M Sasamata; E Hatashita; Y Yamada; K Kuwata; M Fukuoka; K Nakagawa
Journal:  Br J Cancer       Date:  2010-06-01       Impact factor: 9.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.